Post-Treatment Surveillance & Complications

Ductal Breast Carcinoma - Right Mastectomy + Chemotherapy

1. Surveillance Schedule After Mastectomy

Clinical Monitoring

• History and physical examination (including inspection and palpation of the chest wall, contralateral breast, and regional lymph node basins) at every follow-up visit
• Approximately half of locoregional recurrences are detectable on clinical exam
• Any new palpable lump, pain, skin changes, lymphedema, or brachial plexopathy should prompt workup for recurrence

Imaging Surveillance

After mastectomy, recurrences are commonly detected on physical examination (vs. post-lumpectomy recurrences which are often picked up on surveillance mammogram). - Current Surgical Therapy 14e

2. Defining Recurrence After Mastectomy

Types of Recurrence

• Local recurrence: Breast cancer reappearing on the chest wall
• Regional recurrence: Involves ipsilateral axillary, supraclavicular, infraclavicular, or internal mammary nodes

Risk Factors for Postmastectomy Recurrence

• Tumor size >5 cm
• 4 or more positive axillary lymph nodes (increases axillary recurrence rate to >20%)
• Positive surgical margins

Timing

• Median time to recurrence after mastectomy: 2-3 years (vs. 3-4 years after breast conservation therapy)
• Within 10 years: 5-10% of patients after mastectomy experience locoregional recurrence

Presenting Signs

• Clinical mass or multiple small nodules on the chest wall or overlying skin, near the mastectomy scar
• Inflammatory skin changes without a mass
• Painless axillary or supraclavicular mass
• Lymphedema or brachial plexopathy should also trigger workup

5-Year Survival by Site of Recurrence

3. Recurrence Risk Stratification by Tumor Biology

• Luminal A (ER/PR+, HER2-): Low long-term risk of distant metastasis
• Luminal B (ER/PR+, HER2+): Higher initial distant recurrence risk, decreases after first 5 years
• Triple-negative breast cancer (TNBC): Highest recurrence risk, more locally aggressive, tends to recur earlier than receptor-positive subtypes

Genomic Assays to Guide Ongoing Risk Assessment

• Oncotype Dx (21-gene): For ER+/HER2- early-stage cancers - recurrence score 0-100
• MammaPrint (70-gene): Validated for early-stage tumors <5 cm with 0-3 positive nodes
• These tools help determine whether adjuvant chemotherapy meaningfully reduces relapse risk (TAILORx and MINDACT trials)

4. Adjuvant Endocrine Therapy (ongoing surveillance component)

• Premenopausal women: Tamoxifen OR aromatase inhibitor (AI) + ovarian suppression (preferred for women ≤35 years or high recurrence risk)
• Postmenopausal women: Aromatase inhibitor is standard of care
• Duration: 5-10 years
• For HER2+ tumors: Adjuvant trastuzumab reduces relapse and improves survival; pertuzumab may be added
• Washington Manual of Medical Therapeutics

5. Complications to Monitor

A. Lymphedema (Breast Cancer-Related Lymphedema - BCRL)

• Incidence: ~21% of breast cancer patients undergoing treatment
• Risk factors: Axillary node dissection (especially with large number of nodes resected), mastectomy, higher BMI, radiation therapy, sedentary lifestyle
• Symptoms: Arm swelling, heaviness, tightness, pain, decreased range of motion - affects fine motor skills and activities of daily living
• Psychological impact: Anxiety, depression, distress (constant reminder of diagnosis)
• Management: Physical/occupational therapy, compression garments; surgical options include lymphatic grafting or lymphatic-venous anastomosis
• Sabiston Textbook of Surgery, 11e

B. Cardiac Complications (Chemotherapy-Related)

• Most common: Cardiomyopathy / reduced LVEF, progressive and can lead to CHF
• Risk increases with cumulative dose; LVEF at completion of chemotherapy is an independent predictor of cardiotoxicity risk
• Monitoring: Serial echocardiography during and after chemotherapy
• Prevention: Dexrazoxane (FDA-approved Top 2β inhibitor) can reduce anthracycline cardiotoxicity

• Causes cardiomyopathy that is more often reversible than anthracycline-related, but may persist in ~1/3 of affected patients
• Braunwald's Heart Disease, 12e; Harrison's Principles of Internal Medicine, 22e

C. Post-Mastectomy Radiation Complications

• Radiation fibrosis of the chest wall
• Brachial plexopathy
• Increased risk of secondary malignancy (rare)
• Exacerbation of lymphedema risk

D. Psychological & Quality-of-Life Complications

• Body image disturbance and grief after mastectomy
• Chemo brain (cognitive impairment): Memory and concentration issues after chemotherapy
• Fatigue: Often persistent post-treatment
• Menopausal symptoms: Chemotherapy-induced premature menopause in premenopausal women - hot flushes, vaginal dryness, osteoporosis risk
• Sexual dysfunction

E. Bone Health

• Chemotherapy-induced ovarian failure and aromatase inhibitor use both accelerate bone density loss
• Baseline DEXA scan and calcium/vitamin D supplementation recommended; bisphosphonates may be added

6. Workup When Recurrence is Suspected

1. Core biopsy to confirm diagnosis
2. Re-evaluate hormone receptor (ER/PR) and HER2 status - receptor phenotype can change at recurrence
3. Full metastatic staging: CT chest/abdomen/pelvis + bone scan ± PET-CT
4. Brain MRI if CNS symptoms
5. Multidisciplinary team review for treatment planning

• Current Surgical Therapy 14e; Mulholland & Greenfield's Surgery, 7e

Recent Evidence

• Physical examination for recurrence detection (PMID: 39909790, Clin Breast Cancer 2025): Confirms value of clinical exam in post-treatment follow-up
• Circulating tumor DNA (ctDNA) in early breast cancer (PMID: 41729350, Breast Cancer Res Treat 2026): ctDNA is emerging as a sensitive marker for early detection of recurrence - may be integrated into future surveillance protocols